Very Young Breast Cancer in a Referral Center in Tehran, Iran: Review of 55 Cases Aged 25 or Less throughout 33 Years

Alipour, Sadaf; Omranipour, Ramesh; Jahanzad, Issa; Bagheri, Khojasteh

doi:10.7314/apjcp.2013.14.11.6529

Cited by 17 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cut off age limit to designate the patient as young is different and most of the series treating this subject have examined breast carcinoma in young women under 35 [4]. Few series [4,[6][7][8][9] have addressed the topic of breast cancer occurring in women in their teens or early 20s. These studies have revolved around limited number of cases with the largest series to date by Alipour S et al [9] in which 55 women were evaluated.…”

Section: Introductionmentioning

confidence: 99%

“…Few series [4,[6][7][8][9] have addressed the topic of breast cancer occurring in women in their teens or early 20s. These studies have revolved around limited number of cases with the largest series to date by Alipour S et al [9] in which 55 women were evaluated. No Tunisian series of breast cancer before 25 years-old are available, which inspired the current retrospective study of a series including 25 patients of early onset breast cancer diagnosed under the age of 25 years over a period of 21 years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

OM.Breast Cancer in Very Young Women Aged 25 Year-Old or Below in the Center of Tunisia and Review of the Literature

Abdelkrim

Fathallah

Rouatbi

et al. 2015

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Breast cancer in very young women under 40 or 35 years attracted a widespread attention. Few studies have focused on women aged below 25 years. The aim of this study was to evaluate the situation of breast cancer in women ≤25 years in the center of Tunisia. Retrospective review from 1993 to 2013. Clinical, histopathological, therapeutic and outcome data were recorded. Cases were classified into different molecular subtypes based on the immunohistochemistry-based definitions. The series included 25 patients. The mean duration of symptoms was 7.5 months. The most common presenting symptom was a palpable mass. Four patients had at least one relative diagnosed with breast cancer. Mammography combined with ultrasound was suggestive of malignancy in 60 % of cases. Curative surgical treatment could be offered in 19 cases. The mean tumor size was 39 mm. Nodal metastases were detected in 9/18 cases. Twenty cases could be classified into: luminal A (5 cases), luminal B (6 cases), Her-2 (1 case), triple negative (6 cases) and unclassified (2 cases). Two women experienced locoregional recurrence and 6 had distant recurrence. Asynchronous contralateral breast cancer occurred in one case. The overall survival at 5 and 10 years was 85 and 75 % respectively. The survival was significantly lower in grade III tumors (p = 0.04) and triple negative tumors (p = 0.03). Breast cancer in women ≤25 years is uncommon. An adequate medical education of young women and physicians is necessary.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

OM.Breast Cancer in Very Young Women Aged 25 Year-Old or Below in the Center of Tunisia and Review of the Literature

Abdelkrim

Fathallah

Rouatbi

et al. 2015

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Patients with this type of breast cancer are typically less than 40 years old (16). This kind of breast cancer is associated with a worse prognosis and does not respond to typical treatments and has the morphology of epithelial cells with substantial invasion (17). In this study, MDA-MB 231 cell line was used to evaluate this type of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Gene Expression of Hedgehog Signaling Pathway Components in Response to Quinacrine in MDA-MB 231 Cells

et al. 2020

View full text Add to dashboard Cite

Background: Hedgehog signaling pathway abnormality plays an important role in the development of various cancers. PTCH1 and SMO proteins are essential receptors in the hedgehog signaling pathway. Quinacrine as a derivative of 9-aminoacridine revealed an inhibitory effect on the growth of some cancer cells. Triple-negative breast cancer with stem cell-like characteristics remains a poor prognostic type. Objectives: In this study, the effect of quinacrine on patched1 protein receptor (PTCH1) and smoothened protein receptor (SMO) gene expression in the hedgehog signaling pathway was evaluated in MDA-MB 231 breast cancer cell line. Methods: Toxicity of quinacrine was determined based on the MTT assay results. MDA-MB 231 breast cancer cells were treated with 0.5 µM quinacrine for 72 hours. The alteration of the hedgehog signaling pathway was studied by quantitative assessment of PTCH1 and SMO gene expression. Results were evaluated using t-test and were analyzed based on P < 0.05. Results: This study showed that 0.5 µM quinacrine decreases SMO gene expression involved in the hedgehog signaling pathway (-2.1 fold) in MDA-MB 231 breast cancer cell line (P = 0.007). Quinacrine had no significant effect on PTCH1 gene expression (P = 0.059). Conclusions: The SMO gene inhibition by quinacrine could affect breast cancer cells growth with respect to its oncogenic role.

show abstract

“…In Asian women, breast cancer presents relatively earlier compared to the Western countries and the incidence of breast cancer among young women under 40 years of age is relatively high. Recent studies from Asia have shown that 11% to as high as 28% of all breast cancers are diagnosed in women under 40 years of age and the incidence in young women is increasing in the Asian population [1][2][3][4][5][6][7][8][9][10]. Various studies have shown that women who develop breast cancer at a younger age (< 40 years) tend to have more aggressive disease with worse clinicopathological features.…”

Section: Introductionmentioning

confidence: 99%

“…Percentage of young Asian women with risk factors for breast cancer is signi cant [1][2][3][4][5][6][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Differences in clinicopathological features and molecular phenotype of breast carcinoma between patients younger than 40 years and those who are older: A study from Pakistan

Idress

Rasheed

Abdul‐Ghafar³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The debate whether breast cancer in women under 40 years of age is distinct from breast cancer in women above 40 is still inconclusive with various published studies providing conflicting evidence. The majority of studies however suggest that breast cancer in younger women (< 40) is more aggressive with worse clinicopathological features. However, the issue is by no means settled and a number of studies are still going on. Our objective was to analyze different clinicopathological variables and determine whether statistically significant differences are present between those under 40 and those above 40 years of age. The present paper contributes to this debate by reporting our findings. Methods Descriptive cross sectional study of 482 breast cancer cases reported between January and December 31, 2016 which included 380 patients (above 40 years of age) and 102 (under 40 years of age). Variables included grade, stage, axillary lymph node metastases, lymphovascular invasion and molecular groups. p-value less than 0.05 was taken as significant. Results Over 21% patients were younger than 40 years. Differences in histologic grade, stages of T1, T2, and T4, Estrogen Receptor (ER) and Progesterone Receptor (PR) status, Her2neu status, triple negativity and molecular groups between patients younger than 40 years and those older than 40 years were statistically insignificant. Differences in stage T3, axillary metastases and lymphovascular invasion were statistically significant. Conclusion Statistically significant differences were noted in some clinicopathological variables. Majority of variables indicating more aggressive disease were seen in patients older than 40 years of age. Additional studies with larger number of patients under 40 years of age are required to resolve the issue conclusively so that young women with breast cancer are not treated too aggressively unless there is unequivocal statistical evidence that breast cancer is more aggressive in patients under 40 years of age.

show abstract

Very Young Breast Cancer in a Referral Center in Tehran, Iran: Review of 55 Cases Aged 25 or Less throughout 33 Years

Cited by 17 publications

References 13 publications

OM.Breast Cancer in Very Young Women Aged 25 Year-Old or Below in the Center of Tunisia and Review of the Literature

OM.Breast Cancer in Very Young Women Aged 25 Year-Old or Below in the Center of Tunisia and Review of the Literature

Evaluation of the Gene Expression of Hedgehog Signaling Pathway Components in Response to Quinacrine in MDA-MB 231 Cells

Differences in clinicopathological features and molecular phenotype of breast carcinoma between patients younger than 40 years and those who are older: A study from Pakistan

Contact Info

Product

Resources

About